Skip to Main Content

Author Details

Sangdun Choi
Ajou University
1995
159
43
PMIDPaper TitleJournal TitlePublished Year
36950681Modeling structure-activity relationships with machine learning to identify GSK3-targeted small molecules as potential COVID-19 therapeutics.Front Endocrinol (Lausanne)2023
36950681Modeling structure-activity relationships with machine learning to identify GSK3-targeted small molecules as potential COVID-19 therapeutics.Front Endocrinol (Lausanne)2023
34287999Structural insights into the distinctive RNA recognition and therapeutic potentials of RIG-I-like receptors.Med Res Rev2022
35456005Role of Plant-Derived Active Constituents in Cancer Treatment and Their Mechanisms of Action.Cells2022
36142620Toll-like Receptor Mediation in SARS-CoV-2: A Therapeutic Approach.Int J Mol Sci2022
35990491Unraveling the Tomaralimab Epitope on the Toll-like Receptor 2 via Molecular Dynamics and Deep Learning.ACS Omega2022
34287999Structural insights into the distinctive RNA recognition and therapeutic potentials of RIG-I-like receptors.Med Res Rev2022
35196855Novel Small-Molecule Inhibitor of NLRP3 Inflammasome Reverses Cognitive Impairment in an Alzheimer's Disease Model.ACS Chem Neurosci2022
35456005Role of Plant-Derived Active Constituents in Cancer Treatment and Their Mechanisms of Action.Cells2022
36142620Toll-like Receptor Mediation in SARS-CoV-2: A Therapeutic Approach.Int J Mol Sci2022
35990491Unraveling the Tomaralimab Epitope on the Toll-like Receptor 2 via Molecular Dynamics and Deep Learning.ACS Omega2022
35196855Novel Small-Molecule Inhibitor of NLRP3 Inflammasome Reverses Cognitive Impairment in an Alzheimer's Disease Model.ACS Chem Neurosci2022
32885758Origanum vulgare L.: In vitro Assessment of Cytotoxicity, Molecular Docking Studies, Antioxidant and Anti-inflammatory Activity in LPS Stimulated RAW 264.7 Cells.Med Chem2021
37475994Intravenous Administration of Toll-Like Receptor Inhibitory Peptide 1 is Effective for the Treatment of Systemic Lupus Erythematosus in a <i>Mus musculus</i> Model.J Rheum Dis2021
33803178Role of Thioredoxin-Interacting Protein in Diseases and Its Therapeutic Outlook.Int J Mol Sci2021
33997877Injectable <i>in situ</i> forming hydrogel gene depot to improve the therapeutic effect of STAT3 shRNA.Biomater Sci2021
33946869Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication.Cells2021
33562802A Cell-Penetrating Peptide That Blocks Toll-Like Receptor Signaling Protects Kidneys against Ischemia-Reperfusion Injury.Int J Mol Sci2021
34206009Computational-Driven Epitope Verification and Affinity Maturation of TLR4-Targeting Antibodies.Int J Mol Sci2021
34203170Molecular Basis for the Activation of Human Innate Immune Response by the Flagellin Derived from Plant-Pathogenic Bacterium, <i>Acidovorax avenae</i>.Int J Mol Sci2021
32885758Origanum vulgare L.: In vitro Assessment of Cytotoxicity, Molecular Docking Studies, Antioxidant and Anti-inflammatory Activity in LPS Stimulated RAW 264.7 Cells.Med Chem2021
33401508Functional Comparison between VP64-dCas9-VP64 and dCas9-VP192 CRISPR Activators in Human Embryonic Kidney Cells.Int J Mol Sci2021
34671606Toll-Like Receptors as a Therapeutic Target in the Era of Immunotherapies.Front Cell Dev Biol2021
34901007CRISPR/Cas System and Factors Affecting Its Precision and Efficiency.Front Cell Dev Biol2021
34502033Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations.Int J Mol Sci2021
34604731Scaffold printing using biodegradable poly(1,4-butylene carbonate) ink: printability, <i>in vivo</i> physicochemical properties, and biocompatibility.Mater Today Bio2021
34884569Toll-like Receptor Signaling Inhibitory Peptide Improves Inflammation in Animal Model and Human Systemic Lupus Erythematosus.Int J Mol Sci2021
34480409Endogenous Stem Cell-Based In Situ Tissue Regeneration Using Electrostatically Interactive Hydrogel with a Newly Discovered Substance P Analog and VEGF-Mimicking Peptide.Small2021
37475994Intravenous Administration of Toll-Like Receptor Inhibitory Peptide 1 is Effective for the Treatment of Systemic Lupus Erythematosus in a <i>Mus musculus</i> Model.J Rheum Dis2021
33562802A Cell-Penetrating Peptide That Blocks Toll-Like Receptor Signaling Protects Kidneys against Ischemia-Reperfusion Injury.Int J Mol Sci2021
33803178Role of Thioredoxin-Interacting Protein in Diseases and Its Therapeutic Outlook.Int J Mol Sci2021
34884569Toll-like Receptor Signaling Inhibitory Peptide Improves Inflammation in Animal Model and Human Systemic Lupus Erythematosus.Int J Mol Sci2021
34901007CRISPR/Cas System and Factors Affecting Its Precision and Efficiency.Front Cell Dev Biol2021
34502033Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations.Int J Mol Sci2021
34671606Toll-Like Receptors as a Therapeutic Target in the Era of Immunotherapies.Front Cell Dev Biol2021
34604731Scaffold printing using biodegradable poly(1,4-butylene carbonate) ink: printability, <i>in vivo</i> physicochemical properties, and biocompatibility.Mater Today Bio2021
34480409Endogenous Stem Cell-Based In Situ Tissue Regeneration Using Electrostatically Interactive Hydrogel with a Newly Discovered Substance P Analog and VEGF-Mimicking Peptide.Small2021
34206009Computational-Driven Epitope Verification and Affinity Maturation of TLR4-Targeting Antibodies.Int J Mol Sci2021
34203170Molecular Basis for the Activation of Human Innate Immune Response by the Flagellin Derived from Plant-Pathogenic Bacterium, <i>Acidovorax avenae</i>.Int J Mol Sci2021
33946869Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication.Cells2021
33997877Injectable <i>in situ</i> forming hydrogel gene depot to improve the therapeutic effect of STAT3 shRNA.Biomater Sci2021
33401508Functional Comparison between VP64-dCas9-VP64 and dCas9-VP192 CRISPR Activators in Human Embryonic Kidney Cells.Int J Mol Sci2021
31054927Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases.Semin Cancer Biol2020
32325904A Computational Probe into the Structure and Dynamics of the Full-Length Toll-Like Receptor 3 in a Phospholipid Bilayer.Int J Mol Sci2020
32023919TLR4-Targeting Therapeutics: Structural Basis and Computer-Aided Drug Discovery Approaches.Molecules2020
32014819A peptide derived from the core β-sheet region of TIRAP decoys TLR4 and reduces inflammatory and autoimmune symptoms in murine models.EBioMedicine2020
32012718Toll-like Receptors from the Perspective of Cancer Treatment.Cancers (Basel)2020
32012695The Roles of the NLRP3 Inflammasome in Neurodegenerative and Metabolic Diseases and in Relevant Advanced Therapeutic Interventions.Genes (Basel)2020
32220799The αC helix of TIRAP holds therapeutic potential in TLR-mediated autoimmune diseases.Biomaterials2020
33200028Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization.Comput Struct Biotechnol J2020
  • 1 - 50 of 318

Recommended Authors

College of Life Science and Engineering, Southwest Jiaotong University
Career Start Year 2015
Number of shared co-authors 0
Research Center for Nano-Biomaterials, Sichuan University
Career Start Year 2013
Number of shared co-authors 0
National University of Sciences and Technology (NUST)
Career Start Year 2012
Number of shared co-authors 0
Henan University
Career Start Year 2010
Number of shared co-authors 0
University of North Carolina School of Medicine
Career Start Year 2010
Number of shared co-authors 0
Mid and South Essex NHS Foundation Trust
Career Start Year 2009
Number of shared co-authors 0
Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences
Career Start Year 2006
Number of shared co-authors 0
Institute of Insect Science and Technology, South China Normal University
Career Start Year 2006
Number of shared co-authors 0
National Institute of Arthritis
Career Start Year 2005
Number of shared co-authors 0
West China Hospital, Sichuan University
Career Start Year 2005
Number of shared co-authors 0
Jilin University
Career Start Year 2005
Number of shared co-authors 0
Johns Hopkins University School of Medicine
Career Start Year 2004
Number of shared co-authors 0
University Hospital Bonn
Career Start Year 2004
Number of shared co-authors 0
McGill Research Centre for Studies in Aging
Career Start Year 2003
Number of shared co-authors 0
United States Army Medical Research Institute of Infectious Diseases
Career Start Year 2003
Number of shared co-authors 0
Center for Biomolecular and Cellular Structure, Institute for Basic Science (IBS)
Career Start Year 2003
Number of shared co-authors 0
Research Institute for Medical and Health Sciences, University of Sharjah
Career Start Year 2001
Number of shared co-authors 0
College of Plant Protection, Southwest University
Career Start Year 2001
Number of shared co-authors 0
Frazer Institute, The University of Queensland
Career Start Year 2001
Number of shared co-authors 0
Boston Children's Hospital
Career Start Year 2001
Number of shared co-authors 3
the Second Affiliated Hospital of Guangzhou University of Chinese Medicine
Career Start Year 2000
Number of shared co-authors 0
Institute of Pathogens and Vectors, Dali University
Career Start Year 1998
Number of shared co-authors 0
Kaohsiung Medical University
Career Start Year 1998
Number of shared co-authors 0
College of Science & Industry Convergence, Ewha Womans University
Career Start Year 1997
Number of shared co-authors 2
Pondicherry University
Career Start Year 1997
Number of shared co-authors 1
Obstetrics and Gynecology Hospital of Fudan University
Career Start Year 1997
Number of shared co-authors 0
Case Western Reserve University.
Career Start Year 1995
Number of shared co-authors 1
Institute for Systems Biology
Career Start Year 1993
Number of shared co-authors 0
Xijing Hospital, The Fourth Military Medical University
Career Start Year 1992
Number of shared co-authors 0
The Chinese University of Hong Kong
Career Start Year 1979
Number of shared co-authors 1

Collaborators

Co-authored papers 7
Co-authored papers 6
Chonbuk National University Hospital
Co-authored papers 6
Arizona Genomics Institute, University of Arizona
Co-authored papers 5
Co-authored papers 5
Co-authored papers 4
Co-authored papers 4
Co-authored papers 3
Co-authored papers 3
University of California
Co-authored papers 3
Co-authored papers 3
Co-authored papers 3
Co-authored papers 3
Co-authored papers 3
Asan Medical Center, University of Ulsan College of Medicine
Co-authored papers 3
Co-authored papers 3
J. Craig Venter Institute
Co-authored papers 3
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
College of Korean Medicine, Kyung Hee University
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Harvard Medical School
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2